同心医疗IPO获受理，冲刺“人工心脏出海第一股”

Core Viewpoint - Suzhou Tongxin Medical Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, indicating a significant step towards public listing and capital raising for its innovative medical devices [1] Company Overview - Established in 2008, the company focuses on the research, development, and commercialization of full magnetic levitation ventricular assist devices, commonly referred to as artificial hearts [1] - The company has developed a global business system with operational entities in China, the United States, and Europe, achieving rapid revenue growth in both China and the U.S. [1] Product Development - The company's first product, CH-VAD, entered the special approval process for innovative medical devices in China in 2016, with the first human implantation completed in 2017 [1] - In November 2021, the product received approval from the National Medical Products Administration, becoming the first fully magnetic levitation artificial heart product in China with complete independent intellectual property rights [1] - A notable milestone includes a patient who successfully transitioned to heart transplantation after living with the implanted artificial heart for seven years [1]